There are currently 10 active clinical trials seeking participants for Malignant Melanoma research studies. The states with the highest number of trials for Autism participants are California, Florida, New York and Texas.
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Recruiting
This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Florida Cancer Specialists - Lake Nona, Orlando, Florida +1 locations
Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
Recruiting
Study CP-MGC018-02 is a study of vobramitamab duocarmazine (MGC018) in combination with lorigerlimab (MGD019). The study is designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and preliminary antitumor activity. Participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors including, but not limited to, metastatic castration-resistant prostate cancer (mCRPC), melanoma, pancreatic cancer, hepatocellular carc... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: University of California, Los Angeles, Los Angeles, California +9 locations
Conditions: Advanced Solid Tumor, Castration-Resistant Prostatic Cancer, Malignant Melanoma, Pancreatic Ductal Carcinoma, Hepatocellular Cancer, Epithelial Ovarian Cancer, Renal Cell Carcinoma
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
Recruiting
This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: START Midwest, Grand Rapids, Michigan +4 locations
Conditions: Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma, Ras (Kras or Nras) Gene Mutation, BRAF Gene Mutation, CRAF Gene Mutation, Non-Small Cell Lung Carcinoma, Thyroid Carcinoma, Gliomas, Malignant
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Recruiting
This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced solid malignancies. Patients will be screened and evaluated to determine whether or not they meet stated inclusion criteria. Enrolled subjects will undergo leukapheresis to enable the ex vivo generation of CRX100. Patients with non-small cell lung cancer (NSCLC), ovaria... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/07/2024
Locations: HonorHealth Research Institute, Scottsdale, Arizona +2 locations
Conditions: Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Osteosarcoma, Epithelial Ovarian Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Malignant Melanoma
Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors
Recruiting
This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/11/2024
Locations: UC San Diego Moores Cancer Center, La Jolla, California +12 locations
Conditions: Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Cervical Cancer, Microsatellite Instability High, Gastric Cancer, GastroEsophageal Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Recruiting
Patients with Small Cell Lung Cancer, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA) to assess safety and tolerability
Gender:
All
Ages:
16 years and above
Trial Updated:
08/01/2023
Locations: HonorHealth, Scottsdale, Arizona +7 locations
Conditions: SCLC, Malignant Melanoma, Sarcoma
Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma
Recruiting
Activation of the RIG-I innate immune pathway and increased expression of tumor antigens and pro-immune genes by DEC-C during Nivolumab treatment may enhance the frequency and activity of anti-tumor immune cells (CD4+ and CD8+ T-cells, NK cells) and reduce the frequency and activity of immunosuppressive cells. This may increase the overall effectiveness and success of Nivolumab treatment. This pilot clinical trial will demonstrate whether combinatorial immunotherapeutic approaches that target ep... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
06/12/2023
Locations: University of Colorado Hospital, Aurora, Colorado
Conditions: Malignant Melanoma
RAPA-201 Therapy of Solid Tumors
Recruiting
The therapy of solid tumors has been revolutionized by immune therapy, in particular, approaches that activate immune T cells in a polyclonal manner through blockade of checkpoint pathways such as PD-1 by administration of monoclonal antibodies. In this study, the investigators will evaluate the adoptive transfer of RAPA-201 cells, which are checkpoint-deficient polyclonal T cells that represent an analogous yet distinct immune therapy treatment platform for solid tumors. RAPA-201 is a second-g... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2023
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Solid Tumor, Breast Cancer, Small Cell and Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Gastric Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of Nasopharynx, Squamous Cell Carcinoma of Other Specified Sites of Skin, Carcinoma of Unknown Primary, Bladder Cancer, Malignant Melanoma
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
Recruiting
The microbiome has the potential to serve as a robust biomarker of clinical response to immunotherapy. Additionally, microbial manipulation, through diet, exercise, prebiotics, probiotics, or microbially-derived metabolites, may prove to be beneficial in promoting anti-tumor immune responses. However, large prospective studies in humans with longitudinal sample collection and standardized methods are needed to understand how microbiota and their byproducts affect cancer therapies, particularly a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/25/2022
Locations: Baptist Health Clinical Research, Elizabethtown, Kentucky
Conditions: Non-Small-Cell Lung Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Triple-Negative Breast Cancer
GI Complications in Cancer Immunotherapy Patients
Recruiting
The purpose of this study is to establish a prospective observational cohort of cancer immunotherapy patients with GI side effects in order to identify biomarkers that predict GI complications due to treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2022
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Malignant Melanoma